{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-027041","form_type":"8-K","ticker":"WINT","cik":"0000946486","company_name":"WINDTREE THERAPEUTICS INC /DE/","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.125529+00:00","generated_at":"2026-06-21T21:59:30.649469+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Windtree Q3 net loss $4.1M, licenses KL4 surfactant globally for up to $78.9M milestones","bullets":["Net loss of $4.1M ($0.13 per share) vs $8.2M loss in Q3 2021; operating loss $4.7M vs $8.1M.","R&D expenses fell to $1.5M from $4.7M as focus shifts to istaroxime; G&A decreased to $2.7M.","Global license to Lee's (HK)/Zhaoke for KL4 surfactant platform; up to $78.9M milestones plus double-digit royalties.","Cash $8.4M at Sept 30, expected to fund operations into Q2 2023.","USPTO allowed istaroxime patent for longer infusions; positive SEISMiC study published in European Journal of Heart Failure."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-027041","json":"https://secwatch.observer/filing/0001437749-22-027041.json","markdown":"https://secwatch.observer/filing/0001437749-22-027041.md","text":"https://secwatch.observer/filing/0001437749-22-027041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946486/000143774922027041/0001437749-22-027041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946486/000143774922027041/wint20220823_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T21:59:30.649469+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dee0747b8dd011d7c3eba9e45a1ff494afc2908f","claim":"WINDTREE THERAPEUTICS INC /DE/ reported third quarter ended September 30, 2022 results: net income $4.1 million, EPS ($0.13 per basic share).","evidence_excerpt":"The Company reported a net loss of $4.1 million ( $0.13 per basic share) on 31.1 million weighted-average common shares outstanding for the quarter ended September 30, 2022 , compared to a net loss of $8.2 million ( $0.31 per basic share) on 26.7 million weighted average common shares outstanding for the comparable period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/946486/000143774922027041/0001437749-22-027041-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Net income","value":"$4.1 million"},{"label":"EPS","value":"($0.13 per basic share)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}